CellCentric plans to launch a Phase II/III clinical trial targeting heavily pretreated multiple myeloma patients and has received Fast Track and orphan drug designations from the FDA.
Founders
Azim Surani
Company Description
CellCentric is a clinical-stage biotech company focused on developing a novel oral cancer drug, inobrodib, which targets multiple myeloma with a unique mechanism of action and a strong safety profile.
Market
Cancer treatment
Location
UK
Coinvestors
RA Capital Management, Forbion, Avego Bioscience Capital, BrightEdge